Literature DB >> 11175307

Development of a skin-based metabolic sink for phenylalanine by overexpression of phenylalanine hydroxylase and GTP cyclohydrolase in primary human keratinocytes.

R Christensen1, S Kolvraa, R M Blaese, T G Jensen.   

Abstract

Phenylketonuria, PKU, is caused by deficiency of phenylalanine hydroxylase (PAH) resulting in increased levels of phenylalanine in body fluids. PAH requires the non-protein cofactor BH4 and the rate-limiting step in the synthesis of BH4 is GTP cyclohydrolase I (GTP-CH). Here we show that overexpression of the two enzymes PAH and GTP-CH in primary human keratinocytes leads to high levels of phenylalanine clearance without BH4 supplementation. Integration of multiple PAH and GTP-CH transgenes were achieved after optimized retroviral transduction. Phenylalanine clearance was measured ex vivo in primary human keratinocytes cotransduced with PAH and GTP-CH (more than 370 nmol/24 h/106 cells), a level exceeding that of a human liver cell line (HepG2 cells). Cells overexpressing either one of the enzymes alone did not clear significant amounts of phenylalanine. Transfer of the two genes into the same cell was not necessary, since cocultivation of cells transduced separately with PAH and GTP-CH also resulted in phenylalanine clearance. Thus the experiments indicate metabolic cooperation between cells overexpressing PAH and cells overexpressing GTP-CH, possibly due to intercellular transport of synthesized BH4.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11175307     DOI: 10.1038/sj.gt.3301337

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  4 in total

Review 1.  State-of-the-art 2003 on PKU gene therapy.

Authors:  Zhaobing Ding; Cary O Harding; Beat Thöny
Journal:  Mol Genet Metab       Date:  2004-01       Impact factor: 4.797

2.  The fate of intravenously administered tetrahydrobiopterin and its implications for heterologous gene therapy of phenylketonuria.

Authors:  Cary O Harding; Mark Neff; Krzysztof Wild; Kelly Jones; Lina Elzaouk; Beat Thöny; Sheldon Milstien
Journal:  Mol Genet Metab       Date:  2004-01       Impact factor: 4.797

3.  Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system.

Authors:  Zhaobing Ding; Cary O Harding; Alexandre Rebuffat; Lina Elzaouk; Jon A Wolff; Beat Thöny
Journal:  Mol Ther       Date:  2008-03-11       Impact factor: 11.454

4.  Expression of phenylalanine hydroxylase (PAH) in erythrogenic bone marrow does not correct hyperphenylalaninemia in Pah(enu2) mice.

Authors:  Cary O Harding; Mark Neff; Kelly Jones; Krzysztof Wild; Jon A Wolff
Journal:  J Gene Med       Date:  2003-11       Impact factor: 4.565

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.